Table 2 Glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), AST and ALT levels at baseline and at weeks 4 and 12 after treatment
Diacerein group (n = 18) | Placebo group (n = 17) | |
|---|---|---|
HbA1c (%) | ||
Baseline | 8.4 ± 0.1 | 8.5 ± 0.2 |
Week 4 | 8.1 ± 0.2 (p = 0.14) | 8.5 ± 0.1 (p = 0.76) |
Week 12 | 7.8 ± 0.2 (p < 0.05) | 8.2 ± 0.2 (p = 0.06) |
FPG (mg/dL) | ||
Baseline | 162.9 ± 8.7 | 165.9 ± 10.7 |
Week 4 | 164.4 ± 9.9 (p = 0.88) | 164.4 ± 9.9 (p = 0.88) |
Week 12 | 144.0 ± 0.9 (p = 0.06) | 161.9 ± 13.6 (p = 0.63) |
AST (U/L) | ||
Baseline | 29.3 ± 2.9 | 36.5 ± 3.4 |
Week 4 | 28.8 ± 3.0 (p = 0.76) | 36.1 ± 3.1 (p = 0.90) |
Week 12 | 24.9 ± 2.1 (p = 0.08) | 37.6 ± 3.4 (p = 0.69) |
ALT (U/L) | ||
Baseline | 28.4 ± 2.2 | 28.5 ± 1.5 |
Week 4 | 27.9 ± 2.0 (p = 0.65) | 32.5 ± 3.2 (p = 0.18) |
Week 12 | 26.0 ± 1.7 (p = 0.11) | 31.6 ± 1.7 (p = 0.09) |